Flexion Therapeutics Granted Fast Track Status by the FDA for FX006 for Treatment of Osteoarthritis of the Knee

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/14/2026

1. ADBE
2. SPCX
3. USO
4. SPY
5. RH
6. NVDA
7. RKLB
8. MSFT
9. CRM
10. META

Go back to Flexion Therapeutics Granted Fast Track Status by the FDA for FX006 for Treatment of Osteoarthritis of the Knee

Northland Capital Markets Remains Bullish on Flexion Therapeutics (FLXN) After Being Granted Fast Track Status by FDA

September 2, 2015 9:37 AM EDT

Northland Capital Markets reiterated an Outperform rating and $40.00 price target on Flexion Therapeutics (NASDAQ: FLXN) as the company has been granted fast track status by the FDA for FX006. This reduces the NDA review time to approval to within 6 months versus the standard 10... More